They further showed that miR-449a reduced the percent of S phase cells and increased the percent of G1/G0 phase cells by targeting BCL2 and cyclin D1, leading to the enhancement of the CDDP sensitivity of GC cells (176). The gene discussed is BCL2; the disease is gastric cancer.